We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Horizon and Arrowhead Strike $700 Million Deal to Develop RNAi Therapeutic for Gout
Horizon and Arrowhead Strike $700 Million Deal to Develop RNAi Therapeutic for Gout
Horizon Therapeutics has entered into a $700 million development and licensing deal with Arrowhead Pharmaceuticals for Arrowhead’s investigational RNA interference (RNAi) treatment for gout.